Das R, Blazquez-Gamero D, Bernstein DI, Gantt S, et al. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Infect Dis 2023 Aug 31:S1473-3099(23)00343.
PMID: 37660711